From: Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity
Nanomaterial | Size and charge of the nanomaterial | Models | Autophagy markers examined | Experimental techniques used to evaluate autophagy perturbation | Reference |
---|---|---|---|---|---|
Manganese nanoparticles | 30 - 50 nm* | Rat N27 dopaminergic neuronal cells | LC3 and Beclin 1 | Immunoblot, GFP- LC3 transfection | [79] |
Neodymium oxide nanoparticles | 80 nm* | NCI-H460 human lung cancer cells | None | TEM, acridine orange staining | [80] |
C60 fullerene pentoxifylline dyad nanoparticles | 79 nm# | Mouse neuroblast neuro 2A cells | LC3 | Immunoblot and TEM | [81] |
Fullerenol | 20 nm; negative charge# | LLC-PK1 porcine kidney cells | LC3 | Lysotracker assay, Immunoblot, TEM | [32] |
Gold nanoparticles | 10, 20, 50 nm; negative charge# | Rat kidney (NRK) cells | LC3 | Immunoblot, GFP- LC3 transfection, TEM | [82] |
Iron oxide nanoparticles | 115 nm; negative charge# | A549 human lung cancer cells | LC3, ATG5, ATG12; AKT signaling | Immunoblot | [83] |
Polymeric nanoparticles (Eudragit RS) | 54 nm; positive charge# | NR8383 rat alveolar macrophage cell line | LC3 | Immunoblot, TEM, LC3-Immunostaining | [84] |
EGFR-plasmonic magnetic nanoparticles | 73 nm; negative charge# | Non-small cell lung cancer cells | LC3 | Immunoblot, TEM, GFP-LC3 transfection | [31] |
Yttrium oxide nanoparticles | 177 nm# | HeLa cells | LC3 | Immunoblot, TEM, GFP-LC3 transfection | [85] |
Ytterbium oxide nanoparticles | 279 nm# | ||||
Fullerene C60 nanoparticles | 50-100 nm; negative charge# | MCF-7 human breast cancer cell line | LC3 | Immunoblot, GFP- LC3 transfection | [86] |
Uncoated, ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles | 8 nm; positive charge* | HCEC Human brain endothelial cells | LC3 | Immunoblot, TEM | [87] |
Titanium dioxide nanoparticles | 21 nm; negative charge* | ||||
Silica nanoparticles | 25, 50 nm; negative charge* | ||||
Cadmium selenide quantum dot | 5.1 nm# | LLC-PK1 porcine kidney cells | LC3 | Immunoblot, TEM, Lysotracker assay | [88] |
Indium gallium phosphide quantum dot | 3.7 nm# | ||||
PAMAN Dendrimer | Several different generations (varying in sizes and charge)* | A549 human lung cancer cells; Balb\c mice | LC3, AKT signaling | Immunoblot, TEM, GFP-LC3 transfection | [89] |
Silica nanoparticles (spheres, worms, cylinders) | Several# | A549 human lung cancer cells, RAW 264.7 mouse macrophages | LC3 | Immunoblot, TEM | [27] |
Fullerene C60/70 nanoparticles | 100 nm# | Rat C6 glioma cell line | None | Acridine orange staining | [90] |
Iron core with gold shell nanoparticles | 10 nm# | OEMC1 human oral cancer cell line | LC3 | Immunoblot, TEM, LC3 Immunostaining | [91] |
Titanium dioxide nanoparticles | <25 nm* | HT29 human colon cancer cell line | None | GFP-LC3 transfection | [92] |
Palladium nanoparticles | 5-10 nm | Peripheral blood mononuclear cells (PBMC) | LC3 | TEM | [93] |
Single walled carbon nanotube- carboxylic acid | nanoscale* | A549 human lung cancer cell line/Balb/c mice | LC3, AKT signaling | Immunoblot, TEM, ATG6 siRNA transfection | [94] |
Gold nanoparticles | 22 nm; negative charge# | MRC-5 human lung fibroblast cells | LC3, ATG7 | Immunoblot, TEM | [95] |
Fullerene C60 nanocrystals | 20-100 nm# | MCF-7 human breast cancer cell line, HeLa human cervical cancer cell line | LC3 | Immunoblot, TEM, GFP-LC3 transfection | [96] |
Samarium oxide; Europium oxide; Gadolinium oxide; Terbium oxide nanoparticles | 50 nm# | HeLa human cervical cancer cell line | LC3 | Immunoblot, TEM, GFP-LC3 transfection | [97] |
Fullerenol nanoparticles | 7.1 nm# | HUVEC human umbilical vein endothelial cell line | LC3 | Immunoblot, TEM | [98] |
Quantum dots | nanoscale* | Human mesenchymal stem cells | LC3 | LC3 immunostaining, TEM | [30] |
Alpha alumina nanoparticles | 60 nm# | Dendritic cells | LC3 | LC3 immunostaining, Immunoblot, TEM | [28] |